Sager joins Genesis Cancer and Blood Institute
Genesis Cancer and Blood Institute, an American Oncology Network LLC partner, recently announced the addition of medical oncologist Dr. Kristen Sager.
She will work alongside Drs. Timothy Webb, Robert Muldoon, Stephen “Fred” Divers, Lynn Cleveland, Lingyi Chen and Sunil Kakadia.
Sager received her medical degree from Louisiana State University Medical Center and completed her internal medicine residency followed by a hematology-oncology fellowship at Texas A&M College of Medicine. Sager specializes in all cancer types and blood disorders and will be providing care at the Mena and Russellville clinics, the release said.
“We are excited to have Dr. Sager join our practice. She loves the relationships that can be built with patients and their families in a small town and is passionate about bringing the newest and best cancer treatments to these communities,” Genesis medical oncologist Dr. Timothy Webb said in the release.
“The Genesis team now consists of seven medical oncologists and six advanced practice providers across the 10 Arkansas locations. The practice is committed to providing the community with innovative cancer care that is delivered holistically and based on research and evidence-based medicine. Through these services, cancer patients have access to a diverse range of services for diagnosis, treatment, clinical trials, survivorship and patient support that is close to home, limiting their need to travel far to receive care,” the release said.
“Dr. Sager treats each patient and their family with the same enthusiasm and compassion she would have for her own family. She comforts them during what is a very frightening moment in their lives, and they appreciate the one-on-one attention,” AON President and Chief Development Officer Brad Prechtl said in the release.
“We are very pleased to welcome Dr. Sager,” AON Chief Executive Officer Todd Schonherz said in the release. “The field of oncology is constantly evolving, and she is committed to providing her patients the most up-todate treatments available.”